Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selective...

Full description

Bibliographic Details
Published in:OncoImmunology
Main Authors: Xinxin Song, Zhuan Zhou, Rui Kang, Daolin Tang
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Subjects:
KRAS-G12C
bispecific T cell engagers
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2141978
Description
Summary:The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.
ISSN:2162-402X

Similar Items